This phase II trial evaluated the safety and activity of the MEK inhibitor binimetinib combined with hydroxychloroquine in patients with advanced KRAS-mutant non-small cell lung cancer. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.